-
Ontology-based systematic classification and analysis of coronaviruses, hosts, and host-coronavirus interactions towards deep understanding of COVID-19
Authors:
Hong Yu,
Li Li,
Hsin-hui Huang,
Yang Wang,
Yingtong Liu,
Edison Ong,
Anthony Huffman,
Tao Zeng,
**gsong Zhang,
Pengpai Li,
Zhi** Liu,
Xiangyan Zhang,
Xianwei Ye,
Samuel K. Handelman,
Gerry Higgins,
Gilbert S. Omenn,
Brian Athey,
Junguk Hur,
Luonan Chen,
Yongqun He
Abstract:
Given the existing COVID-19 pandemic worldwide, it is critical to systematically study the interactions between hosts and coronaviruses including SARS-Cov, MERS-Cov, and SARS-CoV-2 (cause of COVID-19). We first created four host-pathogen interaction (HPI)-Outcome postulates, and generated a HPI-Outcome model as the basis for understanding host-coronavirus interactions (HCI) and their relations wit…
▽ More
Given the existing COVID-19 pandemic worldwide, it is critical to systematically study the interactions between hosts and coronaviruses including SARS-Cov, MERS-Cov, and SARS-CoV-2 (cause of COVID-19). We first created four host-pathogen interaction (HPI)-Outcome postulates, and generated a HPI-Outcome model as the basis for understanding host-coronavirus interactions (HCI) and their relations with the disease outcomes. We hypothesized that ontology can be used as an integrative platform to classify and analyze HCI and disease outcomes. Accordingly, we annotated and categorized different coronaviruses, hosts, and phenotypes using ontologies and identified their relations. Various COVID-19 phenotypes are hypothesized to be caused by the backend HCI mechanisms. To further identify the causal HCI-outcome relations, we collected 35 experimentally-verified HCI protein-protein interactions (PPIs), and applied literature mining to identify additional host PPIs in response to coronavirus infections. The results were formulated in a logical ontology representation for integrative HCI-outcome understanding. Using known PPIs as baits, we also developed and applied a domain-inferred prediction method to predict new PPIs and identified their pathological targets on multiple organs. Overall, our proposed ontology-based integrative framework combined with computational predictions can be used to support fundamental understanding of the intricate interactions between human patients and coronaviruses (including SARS-CoV-2) and their association with various disease outcomes.
△ Less
Submitted 31 May, 2020;
originally announced June 2020.
-
Pharmacogenomics in the Age of GWAS, Omics Atlases, and PheWAS
Authors:
Ari Allyn-Feuer,
Gerald A. Higgins,
Brian D. Athey
Abstract:
The search for causative pharmacogenomic loci is being transformed by integrative omics pipelines, but their outputs have only begun being applied to test design. We assess the direction of the field in light of Biobanks/PheWAS, omics atlases, and AI. We first assess the potential of recent epigenome and spatial genome concepts, datasets, and methods to improve the functionality of PIP-style pipel…
▽ More
The search for causative pharmacogenomic loci is being transformed by integrative omics pipelines, but their outputs have only begun being applied to test design. We assess the direction of the field in light of Biobanks/PheWAS, omics atlases, and AI. We first assess the potential of recent epigenome and spatial genome concepts, datasets, and methods to improve the functionality of PIP-style pipelines. We then discuss new potential methods of genetic test design on the basis of the outputs of such pipelines. We conclude with a vision for a pharmacophenomic atlas, in which omics atlas data, PheWAS associations, and biobank data would be used with AI to design thousands of genetic tests for clinical deployment in an automated parallel process.
△ Less
Submitted 28 August, 2018;
originally announced August 2018.
-
Deep Learning in Pharmacogenomics: From Gene Regulation to Patient Stratification
Authors:
Alexandr A. Kalinin,
Gerald A. Higgins,
Narathip Reamaroon,
S. M. Reza Soroushmehr,
Ari Allyn-Feuer,
Ivo D. Dinov,
Kayvan Najarian,
Brian D. Athey
Abstract:
This Perspective provides examples of current and future applications of deep learning in pharmacogenomics, including: (1) identification of novel regulatory variants located in noncoding domains and their function as applied to pharmacoepigenomics; (2) patient stratification from medical records; and (3) prediction of drugs, targets, and their interactions. Deep learning encapsulates a family of…
▽ More
This Perspective provides examples of current and future applications of deep learning in pharmacogenomics, including: (1) identification of novel regulatory variants located in noncoding domains and their function as applied to pharmacoepigenomics; (2) patient stratification from medical records; and (3) prediction of drugs, targets, and their interactions. Deep learning encapsulates a family of machine learning algorithms that over the last decade has transformed many important subfields of artificial intelligence (AI) and has demonstrated breakthrough performance improvements on a wide range of tasks in biomedicine. We anticipate that in the future deep learning will be widely used to predict personalized drug response and optimize medication selection and dosing, using knowledge extracted from large and complex molecular, epidemiological, clinical, and demographic datasets.
△ Less
Submitted 6 March, 2018; v1 submitted 25 January, 2018;
originally announced January 2018.
